Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 12/20 | 0.48 |
| ▸ | AR | P10275 | 3/20 | 0.39 |
| ▸ | MLYCD | O95822 | 1/20 | 0.38 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.36 |
| ▸ | PDK3 | Q15120 | 2/20 | 0.36 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.36 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.36 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.36 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.36 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13210392 | 0.86 | HSD11B1 (0.59) | HSD11B1ARPDK1PDK2PDK3 | |
| SCHEMBL13239481 | 0.80 | HSD11B1 (0.62) | HSD11B1ARPDK1PDK2PDK3 | |
| SCHEMBL2324355 | 0.77 | HSD11B1 (0.57) | HSD11B1AR | |
| SCHEMBL19642643 | 0.68 | PDK1 (0.51) | HSD11B1ARPDK1PDK2PDK3 | |
| SCHEMBL2904596 | 0.68 | HSD11B1 (0.39) | HSD11B1ARMLYCD | |
| SCHEMBL2904592 | 0.68 | HSD11B1 (0.39) | HSD11B1ARMLYCD | |
| SCHEMBL10165226 | 0.66 | HSD11B1 (0.59) | HSD11B1 | |
| SCHEMBL4440433 | 0.65 | AR (0.60) | AR | |
| SCHEMBL4031416 | 0.65 | KMT2A (0.49) | ARSLC22A12 | |
| SCHEMBL2908187 | 0.65 | HSD11B1 (1.00) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7754890-B2 | Arylsulfones and uses related thereto | AMGEN INC. (US) | 2010-07-13 | — | — | US | disclosed |
| US-20080269283-A1 | ARYLSULFONES AND USES RELATED THERETO | AMGEN INC. | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269283-A1 | ARYLSULFONES AND USES RELATED THERETO | ARSA, SULT2A1, UGT2B7 | HSD11B1 108/4885AR 1801/4885MLYCD 1185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.